Abstract
The provision of essential medicines forms one of the key health systems “building blocks”, as defined by the World Health Organization. Any consideration of access to medicines for children needs to go beyond the mere physical availability and affordability of such medicines. A patient-centred conceptualization of access to health care has emphasized five dimensions: approachability, acceptability, availability and accommodation, affordability and appropriateness. Accordingly, this chapter is concentrated on issues relevant to individuals, households and communities. It focuses on the resources building block of the health system, in relation to availability, accessibility, affordability, acceptability and quality of medicines for children. The impact of health financing, health information and human resources is also examined. Lastly, it considers the impact of market forces, innovation, transparency and donors’ agenda and funding on optimal access to medicines for children.
Keywords
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Management Sciences for Health. MDS-3: managing access to medicines and health technologies. 2011. http://apps.who.int/medicinedocs/documents/s19577en/s19577en.pdf. Accessed 10 Oct 2014.
Gulliford M, Figueroa-Munoz J, Morgan M, Hughes D, Gibson B, Beech R, et al. What does ‘access to health care’ mean? J Health Serv Res Policy. 2002;7:186–8.
Paniz VM, Fassa AG, Maia MF, Domingues MR, Bertoldi AD. Measuring access to medicines: a review of quantitative methods used in household surveys. BMC Health Serv Res. 2010;30:146.
Levesque JF, Harris MF, Russell G. Patient-centred access to health care: conceptualising access at the interface of health systems and populations. Int J Equity Health. 2013;12:18.
Bigdeli M, Jacobs B, Tomson G, Laing R, Ghaffar A, Dujardin B, et al. Access to medicines from a health system perspective. Health Policy Plan. 2013;28:692–704.
World Health Assembly. Better medicines for children (WHA60.20). 2007. http://www.who.int/childmedicines/publications/WHA6020.pdf. Accessed 10 Oct 2014.
Cameron A, Ewen M, Auton M, Dele A. The World Medicines Situation 2011. Medicine prices, availability and affordability. Geneva: World Health Organization; 2011. p. 2011.
Manzi F, Schellenberg JA, Adam T, Mshinda H, Victora CG, Bryce J. Out-of-pocket payments for under-five health care in rural southern Tanzania. Health Policy Plan. 2005;20:i85–93.
Yates R. Women and children first: an appropriate first step towards universal coverage. Bull World Health Organ. 2010;88:474–5.
Gray A. Pediatric pharmacotherapy issues in Africa. Paediatr Drugs. 2009;11:6–8.
Zucker H, Rago L. Access to essential medicines for children: the world health organization’s global response. Clin Pharmacol Ther. 2007;82:503–5.
Hill SR, Gray A, Weber M. Essential medicines for children – setting some standards. Bull World Health Organ. 2007;85:650.
Robertson J, Forte G, Trapsida J-M, Hill S. What essential medicines for children are on the shelf? Bull World Health Organ. 2009;87:231–7.
The Interagency Task Team on the Prevention and Treatment of HIV Infection in Pregnant Women Mothers and Children. Update to the optimal list of paediatric ARV formulations. IATT Meeting Report, Geneva, Switzerland. 2013;11–12.
Fischer Walker C, Fontaine O, Young MW, Black RE. Zinc and low osmolarity oral rehydration salts for diarrhoea: a renewed call to action. Bull World Health Organ. 2009;87:780–6.
Unger CC, Salam SS, Sarker MS, Black R, Cravioto A, El Arifeen S. Treating diarrhoeal disease in children under five: the global picture. Arch Dis Child. 2014;99:273–8.
Larson CP, Koehlmoos TP, Sack DA, Scaling up of Zinc for Young Children (Suzy) Project Team. Scaling up zinc treatment of childhood diarrhoea in Bangladesh: theoretical and practical considerations guiding the SUZY Project. Health Policy Plan. 2012;27:102–14.
Ragupathy R, Tordoff J, Norris P, Reith D. Access to children’s medicines in the United Kingdom, Australia and New Zealand in 1998, 2002 and 2007. Pharm World Sci. 2010;32:386–93.
Milne C-P, Davis J. The pediatric studies initiative: after 15 years have we reached the limits of the law? Clin Ther. 2014;36:156–62.
Mehta PS, Wiernikowski JT, Petrilli JA, Barr RD; Working Group on Essential Medicines of the Pediatric Oncology in Developing Countries Committee of SIOP. 2013. Essential medicines for pediatric oncology in developing countries. Pediatr Blood Cancer. 2013;60:889–91.
Van Riet-Nales DA, Schobben AFAM, Egberts TCG, Rademaker CMA. Effects of the pharmaceutical technologic aspects of oral pediatric drugs on patient-related outcomes: a systematic literature review. Clin Ther. 2010;32:924–38.
Craig SR, Adams LV, Spielberg SP, Campbell B. Pediatric therapeutics and medicine administration in resource-poor settings: a review of barriers and an agenda for interdisciplinary approaches to improving outcomes. Soc Sci Med. 2009;69:1681–90.
Spector JM, Reisman J, Lipsitz S, Desai P, Gawande AA. Access to essential technologies for safe childbirth: a survey of health workers in Africa and Asia. BMC Pregnancy Childbirth. 2013;13:43.
Mendis S, Fukino K, Cameron A, Laing R, Filipe AJ, Khatib O, et al. The availability and affordability of selected essential medicines for chronic diseases in six low- and middle-income countries. Bull World Health Organ. 2007;85:279–88.
Babar ZU, Ibrahim MI, Singh H, Bukahri NI, Creese A. Evaluating drug prices, availability, affordability, and price components: implications for access to drugs in Malaysia. PLoS Med. 2007;4:e82.
Conway J, Bero L, Ondari C, Wasan KM. Review of the quality of pediatric medications in developing countries. J Pharm Sci. 2013;102:1419–33.
Nunan M, Duke T. Effectiveness of pharmacy interventions in improving availability of essential medicines at the primary healthcare level. Trop Med Int Health. 2011;16:647–58.
Cohen-Kohler JC. The morally uncomfortable global drug gap. Clin Pharmacol Ther. 2007;82:610–4.
Myhr K. Access to and price of medicines globally. Tidsskr Nor Laegeforen. 2011;131:2019–21.
Seuba X. A human rights approach to the WHO Model List of Essential Medicines. Bull World Health Organ. 2006;84:408–11.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2015 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Gray, A., Jeena, P., Ojoo, A. (2015). Access to Medicines – More Than Just Affordability. In: MacLeod, S., Hill, S., Koren, G., Rane, A. (eds) Optimizing Treatment for Children in the Developing World. Adis, Cham. https://doi.org/10.1007/978-3-319-15750-4_3
Download citation
DOI: https://doi.org/10.1007/978-3-319-15750-4_3
Publisher Name: Adis, Cham
Print ISBN: 978-3-319-15749-8
Online ISBN: 978-3-319-15750-4
eBook Packages: MedicineMedicine (R0)